EP70: Fenebrutinib in Relapsing MS: FENhance Trial Results Explained
EP70: Fenebrutinib in Relapsing MS: FENhance Trial Results Explained
New Phase 3 data presented at the AAN conference 2026 provide compelling evidence that fenebrutinib may represent a high-efficacy oral treatment option for people living with relapsing multiple sclerosis.
In this exclusive episode, leading experts Prof. Ludwig Kappos (University of Basel & RC2NB) and Dr. Jiwon Oh [NS1] [BD2] (University of Toronto & Barlo MS Centre) join host Brett Drummond to unpack the full FENhance 1 & 2 trial results.
Together, they explore:
- How fenebrutinib performed against teriflunomide in relapsing MS
- Why BTK inhibition continues to generate strong interest across the MS treatment landscape
- What the results reveal about relapse reduction, MRI outcomes, and disability progression
- What the safety profile of fenebrutinib looked like in this cohort of patients
Listen for a deep dive into the science, clinical context, and future implications for MS care.
This episode has been supported by an educational grant from Alexion, AstraZeneca Rare Diseases, Bristol Myers Squibb, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.